Cassava Sciences, Inc.

Cassava Sciences, Inc. (SAVA) is a biotechnology company focused on research and development of therapeutic treatments for neurodegenerative diseases. The company's primary goal is to discover innovative therapies targeting Alzheimer's disease, one of the most devastating cognitive impairing illnesses. Cassava Sciences is developing a drug known as Simufilam, which has undergone clinical trials and has shown promising results in improving cognitive functions in Alzheimer's disease patients. Investing in Cassava Sciences' stock may present an attractive opportunity for investors who closely follow advancements in neurodegenerative disease treatments and seek innovative companies with potential in the biotechnology field.